Comparison between radiofrequency ablation combined with mifepristone and radiofrequency ablation for large uterine fibroids.
Int J Hyperthermia
; 38(1): 777-780, 2021.
Article
en En
| MEDLINE
| ID: mdl-33980123
ABSTRACT
OBJECTIVE:
To evaluate the clinical outcomes of transvaginal ultrasound-guided (US-guided) radiofrequency ablation (RFA) combined with mifepristone for the treatment of large uterine fibroids.METHODS:
Between June 2016 and December 2018, a total of 30 patients with symptomatic uterine fibroids (≥5cm) who underwent transvaginal US-guided RFA combined with mifepristone were included in this retrospective study. A matching cohort of 30 patients underwent transvaginal US-guided RFA without mifepristone as controls. The technical efficacy, complications and mid-term treatment effectiveness were assessed and compared with the controls.RESULTS:
The mean volume of uterine fibroid was 168.3 ± 40.1 cm3. The mean ablation time was 23.5 ± 11.3 min in the combined treatment group, which was demonstrably less than that of the RFA group, which was 45.7 ± 6.8 min. The mean number of punctures was 2.2 ± 0.6 in the combined treatment group, which was significantly less than that of the RFA group. No major complications occurred. The mean percentages of regression of fibroid at 3 and 12 months after the course of the combined treatment were 73.3% and 90.1%, respectively, which were significantly more than those of the RFA group. Quality of life and symptom scores improved in both groups but to a greater extent in the combined treatment group.CONCLUSIONS:
US-guided RFA combined with mifepristone might be a simple, safe and effective alternative for the treatment of large uterine fibroids.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias Uterinas
/
Ablación por Radiofrecuencia
/
Leiomioma
Tipo de estudio:
Observational_studies
Límite:
Female
/
Humans
Idioma:
En
Revista:
Int J Hyperthermia
Asunto de la revista:
NEOPLASIAS
/
TERAPEUTICA
Año:
2021
Tipo del documento:
Article